Clinical Evaluation of a Time-Sequential Biphasic NMN–Resveratrol–Quercetin–Piperine NAD+ Supplement Targeting SIRT1 (BCLC™)

Abstract

Background: Time-sequential biphasic NAD+ formulations are designed to solve the temporal mismatch, poor dissolution, and exposure instability that often limit conventional NMN combinations. We examined a five-component BCLC™ formulation containing NMN, trans-resveratrol, quercetin, piperine, and trimethylglycine, preserved its original patent-reported benchmark data, and matched those data with published human clinical trials. Methods: We retained the original formulation specifications, dissolution and stability results, and in-vitro SIRT1-related benchmarks reported in the source document, then searched PubMed, PubMed Central, and clinical-trial records through March 28, 2026 for adult interventional studies involving NMN, resveratrol, quercetin, or piperine that were relevant to NAD+, SIRT1, insulin sensitivity, oxidative stress, physical function, or bioavailability. Results: In the patent dataset, the leading embodiments achieved 4.1–5.5-fold SIRT1 pathway activation, 95.6–98.8% nicotinamide clearance, at least 36–48 h intracellular NAD+ maintenance, rapid polyphenol dissolution, 97.8–98.5% three-month retention, and material loss no higher than 3.5%. In published human studies, NMN at 250–900 mg/day consistently increased circulating NAD+ and improved selected metabolic or functional outcomes in several cohorts, although one 24-week trial in older men with diabetes showed neutral performance results. Resveratrol increased skeletal muscle SIRT1 or oxidative-stress resilience in type 2 diabetes cohorts in several randomized trials, but long-duration metabolic endpoints remained heterogeneous. Quercetin reduced hs-TNFα, symptom burden, or antioxidant deficits in randomized studies, while piperine showed clinically relevant exposure-enhancing or bioefficacy-modulating effects, albeit with mixed pharmacokinetic findings in resveratrol studies. Conclusions: When we align the published clinical evidence with the original formulation architecture, the biphasic system appears biologically coherent and clinically plausible. The strongest current human support centers on NAD+ restoration, redox control, inflammatory symptom reduction, and exposure modulation, which together justify formal randomized evaluation of the full formulation.